Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.

    Oct 30, 2026DOI: 10.1161/jaha.126.050387Journal ArticleAHA

    Written by: Padmini SelvaganesanMohamad KarnibIrfan HelmyRosita ZakeriYusef Babar SaeedJayakumar SahadevanMohammed Najeeb OsmanAnirban MondalSherry Milfred-LaForestJames C FangYogesh N V ReddyVarun Sundaram

    Find these authors on Roon

    YR
    Dr. Yogesh Reddy
    Advanced Heart Failure · Mayo Clinic College of Medicine

    Summary

    BACKGROUND: To evaluate whether GLP-1 (glucagon-like peptide-1) receptor agonists (GLP-1RAs), compared with DPP4 (dipeptidyl peptidase-4) inhibitors or sulfonylureas, are associated with reduced all-cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction.METHODS: PRAISE-HFpEF (Glucagon-Like Peptide-1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new-user, active-comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP-1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all-cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics.RESULTS: Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP-1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow-up of 1.5 years, GLP-1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64-0.95], P=0.01). Weight loss was modestly greater with GLP-1RAs compared with DPP4 inhibitors/sulfonylurea (-12.9% versus -10.1%).CONCLUSIONS: Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP-1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.
    YRDr. Yogesh Reddy

    Dr. Yogesh Reddy

    Cardiology · Advanced Heart Failure & Transplantation
    Mayo Clinic
    yogesh